期刊文献+

胺碘酮联合氯沙坦治疗阵发性房颤疗效分析 被引量:3

下载PDF
导出
摘要 目的:了解胺碘酮联合氯沙坦对阵发性房颤的复律及复律后窦性心律维持的影响。方法:将86例非瓣膜病阵发性房颤患者分为胺碘酮治疗组和胺碘酮+氯沙坦治疗组,观察治疗24小时、3天和7天时房颤的转复情况。在房颤复律后,继续治疗并随访观察1年,评价两组窦律的维持效果。结果:两组在24小时及3天时房颤的转复率差异无显著性意义(P>0.05),在7天时有显著性意义(P<0.05)。随访1年时两组窦性心律的维持率及左房内径差异均有显著性意义(P<0.05)。结论:胺碘酮联合氯沙坦对阵发性房颤的复律及复律后窦性心律维持均优于单用胺碘酮治疗。
作者 赵春玉
出处 《中国社区医师(医学专业)》 2011年第14期43-43,共1页
  • 相关文献

参考文献3

二级参考文献33

  • 1Wijjfels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation:a study in awake chronically instrumented goats[J]. Circulation, 1995,92(6) : 1954.
  • 2Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure:electrophysiological and electroanatomic mapping in humans[J].Circulation,2003,108(12) : 1461.
  • 3Goette A,Staack T, Rocken C, et al. Increased expression of extracellular signate regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation [J]. J Am Coll Cardiol,2000,35(6) :1669.
  • 4Kalus J,Coleman C, White C. The impact of suppressing the renin-angiotensin system on atrial fibrillation[J]. Clin Pharmacol, 2006,46(1) .. 21.
  • 5Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction[J]. Circulation, 1999,100 : 376.
  • 6Madrid AH,Bueno MG,Rebollo JM,et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomizedstudy[J]. Circulation,2002,106(3) :331.
  • 7Dueharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure:assessment of reduction in mortality and morbidity (CHARM) program[J]. Am Heart, 2006,152 : 86.
  • 8Ozcan C, Jahangir A, Friedman PA, et al. Long - term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med, 2001, 344 (14): 1043-1051
  • 9Wood MA, Brown- Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta -analysis. Circulation, 2000, 101 (10): 1138 - 1144
  • 10Weerasooriya R, Davis M, Powell A, et al. The Australian intervention randomized control of rate in atrial fibrillation trial ( AIRCRAFT). J Am Coll Cardiol, 2003, 41 (10): 1697 - 1702

共引文献78

同被引文献27

  • 1Caiyi LU Shiwen WANG Wei YAN Xingli WU Yuxiao ZHANG Qiao XUE Muyang YAN Peng LIU Rui CHEN Jinyue ZHAI.Evaluation of coronary plaque and stent deployment by intravascular optical coherence tomography in elderly patients with unstable angina and non-ST-elevation myocardial infarction[J].Journal of Geriatric Cardiology,2007,4(1):3-9. 被引量:3
  • 2Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, Tse HF, Lau CP. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes. Cardiovasc Res. 2009 Feb 1;81(2):286-93.
  • 3Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion, of atrial flutter and fibrillation. J Am Board Faro Med. 2011 Jan-Feb;24(1):86-92.
  • 4D?browski R, Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J. 2012;19(3):223-9.
  • 5Singh JP, Kulik A, Levin R, Ellinor PT, Ruskin J, Avom J, Choudhry NK. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Europace. 2012 Sep;14(9):1287-93.
  • 6Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013 Jun 18;127(24):2414-23.
  • 7Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013 Jul;29 (7 Suppl): S24-33.
  • 8Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers[J]. J Am Coil Cardiol,2005 ;45( 11 ) :1832-9.
  • 9Ueng KC,Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after exeternal cardioversion of long-standing persis- tent atrial fibrilation. Results of a prospective and controled study [J]. Eur Heart J,2003 ;24(23 ) :2090-8.
  • 10王红梅.胺碘酮联用氯沙坦对高血压患者阵发性心房颤动的作用[J].山西职工医学院学报,2009,19(2):41-42. 被引量:1

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部